RXRX
Recursion Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +2.9% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 77.22K | $312,175 | n/a | n/a |
| Q2 2026 | 102 | -2 | 264.93M | $972.11M | +5 | −7 |
| Q1 2026 | 107 | +3 | 243.54M | $747.81M | +9 | −7 |
| Q4 2025 | 104 | +2 | 261.79M | $1.07B | +4 | −1 |
| Q3 2025 | 16 | -2 | 173.92M | $848.75M | n/a | −3 |
| Q2 2025 | 16 | 0 | 153.65M | $777.46M | n/a | n/a |
| Q1 2025 | 13 | +3 | 87.35M | $462.12M | +3 | n/a |
| Q4 2024 | 10 | 0 | 84.02M | $567.97M | n/a | n/a |
| Q3 2024 | 9 | +2 | 69.10M | $455.38M | +2 | n/a |
| Q2 2024 | 7 | n/a | 63.72M | $477.87M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 32.35M | -1.3% | $218.66M | 1.8% | ▼ Trim | 3 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 24.86M | -1.5% | $168.08M | 0.1% | ▼ Trim | 3 | SEC ↗ ×4 |
| 3 | State Street Global Advisors ✦ (passive) | 12.58M | n/a | $85.03M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 6.09M | +12.1% | $41.16M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 3.47M | -3.0% | $23.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 2.74M | +1069.5% | $18.52M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.66M | +4.0% | $11.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 131.99K | +17.4% | $893,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 114.94K | +9.4% | $777,029 | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 10 | Millennium Management ✦ | 28.31K | -27.0% | $191,376 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 334.81M shares, $1.02B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $242,000
Director · 25.00K sh · $125,000
Officer, Director · 22.41K sh · $78,822
Director · 30.00K sh · $100,200
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology